

S 6

Biosimilar Red Tape Elimination Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Nov 17, 2022

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Nov 17, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/6>

Sponsor

Name: Sen. Lee, Mike [R-UT]

Party: Republican • **State:** UT • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Nov 17, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Nov 17, 2022)

Biosimilar Red Tape Elimination Act

This bill removes and otherwise modifies certain requirements related to the approval of biosimilars, such as prohibiting the Food and Drug Administration from requiring studies that assess the risks of switching between the biosimilar and the reference biologic.

Actions Timeline

- **Nov 17, 2022:** Introduced in Senate
- **Nov 17, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.